Cysteamine is currently the only
therapy for
nephropathic cystinosis. It significantly improves life expectancy and delays progression to
end-stage kidney disease; however, it cannot prevent it. Unfortunately, compliance to
therapy is often weak, particularly during adolescence. Therefore, finding better treatments is a priority in the field of
cystinosis. Previously, we found that
genistein, an
isoflavone particularly enriched in soy, can revert part of the cystinotic cellular phenotype that is not sensitive to
cysteamine in vitro. To test the effects of
genistein in vivo, we fed 2-month-old wild-type and Ctns-/- female mice with either a control diet, a
genistein-containing diet or a
cysteamine-containing diet for 14 months.
Genistein (160 mg/kg/day) did not affect the growth of the mice or hepatic functionality. Compared with untreated mice at 16 months, Ctns-/- mice fed with
genistein had lower
cystine concentrations in their kidneys, reduced formation of
cystine crystals, a smaller number of LAMP1-positive structures and an overall better-preserved parenchymal architecture.
Cysteamine (400 mg/kg/day) was efficient in reverting the lysosomal phenotype and in preventing the development of renal lesions. These preclinical data indicate that
genistein ameliorates kidney injury resulting from
cystinosis with no side effects.
Genistein therapy represents a potential treatment to improve the outcome for patients with
cystinosis.